Erratum to Barco et al. 'Home treatment of patients with lowrisk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot-PE Trial' (Thromb Haemost 2016; 116: 191-197)

Autor:	Klaus Empen, David Jiménez, Sebastian Schellong, Kurt Quitzau, Michael Christ, Daniel Duerschmied, Christine Espinola-Klein, Martin Schwaiblmair, Matthias Held, Stavros Konstantinides, Jan Beyer-Westendorf, Rupert Bauersachs, Cândida Fonseca, Harald Binder, Mareike Lankeit, Philipp S. Wild, Cecilia Becattini, Stefano Barco
Rok vydání:	2016
Předmět:	Rivaroxaban medicine.medical_specialty medicine.drug_mechanism_of_action business.industry Factor Xa Inhibitor Hematology medicine.disease Pulmonary embolism Internal medicine medicine Cardiology Home treatment business Stroke medicine.drug
Zdroj:	Thrombosis and Haemostasis. 116:775
ISSN:	2567-689X 0340-6245
DOI:	10.1160/th16100001
Popis:	[This corrects the article DOI: 10.1160/TH16-01-0004.].
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65ee5746a8213185aa46458c037d9408 https://doi.org/10.1160/th16100001 Zobrazit plný text záznamu